Berven, Haakon
Kverneng, Simon
Sheard, Erika
Søgnen, Mona
Af Geijerstam, Solveig Amdahl
Haugarvoll, Kristoffer http://orcid.org/0000-0001-9381-1109
Skeie, Geir-Olve
Dölle, Christian http://orcid.org/0000-0003-2427-8130
Tzoulis, Charalampos http://orcid.org/0000-0003-0341-5191
Funding for this research was provided by:
Norges Forskningsråd (288164)
Helse Vest (F-11470, F-12133)
Trond Mohn Foundation
Article History
Received: 24 March 2023
Accepted: 13 November 2023
First Online: 28 November 2023
Competing interests
: International patent applications relating to the use of nicotinamide riboside as a treatment for Parkinson’s disease have been filed by the Technology Transfer Office “Vestlandets Innovasjonsselskap As (VIS)” on behalf of Haukeland University Hospital, Bergen, Norway, with publication authors C.T. and C.D. as inventors. The applications are pending and have the application numbers: PCT/EP2022/067408, PCT/EP2022/067412 and PCT/EP2023/060962. All other authors declare no competing interests.